Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01302834 · ClinicalTrials.gov registry record · Phase 3
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
A Phase 3 study of Head and Neck Cancer and Precancerous Condition, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 987
- Enrollment target
- 20
- Study locations
NCT01302834 is a Phase 3 study of Head and Neck Cancer and Precancerous Condition that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 987 participants, above the 257-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (284% higher). The trial reports 20 study locations across 3 states.
The verdict
NCT01302834, a Phase 3 study of Head and Neck Cancer and Precancerous Condition, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 987 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether radiation therapy is more effective with cisplatin or cetuximab in treating oropharyngeal cancer. PURPOSE: This phase III trial is studying radiation therapy with cisplatin or cetuximab to see how well it works in treating patients with oropharyngeal cancer.
Conditions Studied
Interventions
- DRUG cisplatin
- RADIATION IMRT
- BIOLOGICAL cetuximab
Study Locations (20)
California
- Auburn Radiation Oncology - Auburn
- Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical Center - Burbank
- Radiation Oncology Centers - Cameron Park - Cameron Park
- Mercy Cancer Center at Mercy San Juan Medical Center - Carmichael
- Enloe Cancer Center at Enloe Medical Center - Chico
- City of Hope Comprehensive Cancer Center - Duarte
- Rebecca and John Moores UCSD Cancer Center - La Jolla
- Kaiser Permanente - Division of Research - Oakland - Oakland
- Rohnert Park Cancer Center - Rohnert Park
- Radiation Oncology Center - Roseville - Roseville
- Radiological Associates of Sacramento Medical Group, Incorporated - Sacramento
- Mercy General Hospital - Sacramento
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
- - Santa Clara
- Kaiser Permanente Medical Center - South San Francisco - South San Francisco
- Solano Radiation Oncology Center - Vacaville
Colorado
- Rocky Mountain Cancer Centers - Aurora - Aurora
- Boulder Community Hospital - Boulder
- Penrose Cancer Center at Penrose Hospital - Colorado Springs
Alaska
- Providence Cancer Center - Anchorage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 987 participants |
| Start Date | 2011-06 |
| Est. Completion | 2025-09-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01302834
The ClinicalTrials.gov registry entry for NCT01302834 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 987 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 257-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (284% higher). The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 3 interventions - of which cisplatin is the first listed.
NCT01302834 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Colorado, Alaska.
Frequently Asked Questions
What is clinical trial NCT01302834 about?
NCT01302834 is a clinical study titled "Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab...
What is the current status of trial NCT01302834?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 987 participants. The study started on 2011-06. Estimated completion is 2025-09-04.
What conditions does trial NCT01302834 study?
This clinical trial studies the following conditions: Head and Neck Cancer, Precancerous Condition.
What interventions are being tested in trial NCT01302834?
The interventions under investigation include: cisplatin (DRUG), IMRT (RADIATION), cetuximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01302834?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01302834 being conducted?
This trial has 20 study locations across Alaska, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Addressing Taste Dysfunction With Miraculin in Head and Neck Cancer Patients Receiving Radiation Therapy
RECRUITING · Phase 3
-
ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy
ACTIVE NOT RECRUITING · Phase 3
-
Tumescence in HNC Skin Graft Reconstruction
ACTIVE NOT RECRUITING · Phase 3
-
RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Controlled Trial Of Acupuncture To Prevent Radiation-Induced Xerostomia
ACTIVE NOT RECRUITING · Phase 3
-
Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.